InvestorsHub Logo
Followers 3
Posts 292
Boards Moderated 0
Alias Born 12/21/2022

Re: None

Sunday, 02/26/2023 10:40:39 AM

Sunday, February 26, 2023 10:40:39 AM

Post# of 569
Here is a what Harry Erba, a hematologic oncologist from Duke thinks about Tusp data presented at ASH last year (started from 12 min). Interesting comment on TKIs in CML. He said it is not clear what is better, a more targeted kinase inhibitor or a less targeted kinase inhibitor that is able to overcome resistance pathways.
https://www.onclive.com/view/acute-myeloid-leukemia-updates-from-the-ash-2022-annual-meeting
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent APTO News